Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries

JAMA Internal Medicine

Volumn 176, Issue 8, 2016, Pages 1114-1122

  DeJong, Colette ^a   Aguilar, Thomas ^a   Tseng, Chien Wen ^b,c   Lin, Grace A ^a   Boscardin, W John ^a   Dudley, R Adams ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c PACIFIC HEALTH RESEARCH AND EDUCATION INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; NEBIVOLOL; OLMESARTAN; ROSUVASTATIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PRESCRIPTION DRUG;

ARTICLE; CROSS-SECTIONAL STUDY; DRUG INDUSTRY; DRUG MARKETING; FEMALE; HUMAN; MALE; MEAL; MEDICAL FEE; MEDICARE; PHYSICIAN; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; CATERING SERVICE; CLINICAL PRACTICE; ECONOMICS; GIFT GIVING;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CROSS-SECTIONAL STUDIES; DRUG INDUSTRY; GIFT GIVING; HUMANS; MEDICARE PART D; PHYSICIANS; PRACTICE PATTERNS, PHYSICIANS'; PRESCRIPTION DRUGS; RESTAURANTS; UNITED STATES;

EID: 84980398156     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.2765     Document Type: Article

References (41)

1. Open Payments. Baltimore, MD: Centers for Medicare & Medicaid Services; 2015. https://openpaymentsdata.cms.gov/dataset/General-Payment-Data-with-Identifying-Recipient-In/hrpy-hqv8. Accessed September 15, 2015.
2. Santhakumar S, Adashi EY. The Physician Payment Sunshine Act: testing the value of transparency. JAMA. 2015;313(1):23-24.
3. Groeger L, Ornstein C, Tigas M, Jones RG. Dollars for docs: how industry dollars reach your doctors. New York, NY: ProPublica; 2015. https://projects.propublica.org/docdollars/. Accessed September 20, 2015.
4. Ornstein C, Jones RG, Tigas M. Now there's proof: docs who get company cash tend to prescribe more brand-name meds. New York, NY: ProPublica. https://www.propublica.org/article/doctors-who-take-company-cash-tend-to-prescribe-more-brand-name-drugs. Published March 17, 2016. Accessed April 9, 2016.
5. European Federation of Pharmaceutical Industries and Associations (EFPIA). EFPIA Code on disclosure of transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations. Brussels, Belgium: EFPIA; 2013. http://transparency.efpia.eu/the-efpia-code-2. Accessed April 13, 2016.
6. Rosenbaum L. Conflicts of interest: part 1: reconnecting the dots-reinterpreting industry-physician relations. N Engl J Med. 2015;372 (19):1860-1864.
7. Greenberg SB, Vender JS. Point: should academic physicians lecture as members of industry speaker bureaus? yes. Chest. 2014;146(2): 250-252.
8. Steinbrook R, Kassirer JP, Angell M. Justifying conflicts of interest in medical journals: a very bad idea. BMJ. 2015;350:h2942.
9. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295(4):429-433.
10. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283(3):373-380.
11. Lieb K, Scheurich A. Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS One. 2014;9(10):e110130.
12. Robertson C, Rose S, Kesselheim AS. Effect of financial relationships on the behaviors of health care professionals: a review of the evidence. J Law Med Ethics. 2012;40(3):452-466.
13. Spurling GK, Mansfield PR, Montgomery BD, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med. 2010;7 (10):e1000352.
14. Windmeijer F, de Laat E, Douven R, Mot E. Pharmaceutical promotion and GP prescription behaviour. Health Econ. 2006;15(1):5-18.
15. Huang FY, Weiss DS, Fenimore PG, et al. The association of pharmaceutical company promotional spending with resident physician prescribing behavior. Acad Psychiatry. 2005;29(5): 500-501.
16. Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS. Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts [published online May 9, 2016]. JAMA Intern Med. doi:10.1001/jamainternmed.2016.1709.
17. Perlis RH, Perlis CS. Physician payments from industry are associated with greater Medicare Part D prescribing costs. PLoS One. 2016;11(5):e0155474.
18. Physician Compare. Baltimore, MD: Centers for Medicare & Medicaid Services; 2015. https://www.medicare.gov/physiciancompare/. Accessed September 25, 2015.
19. Medicare Provider Utilization and Payment Data: Part D Prescriber. Baltimore, MD: Centers for Medicare & Medicaid Services; 2015. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Part-D-Prescriber.html. Accessed September 10, 2015.
20. Donohue JM, Morden NE, Gellad WF, et al. Sources of regional variation in Medicare Part D drug spending. N Engl J Med. 2012;366(6):530-538.
21. Rizzo JA. Advertising and competition in the ethical pharmaceutical industry: the case of antihypertensive drugs. J Law Econ. 1999;42:89-116.
22. Shrank WH, Choudhry NK, Agnew-Blais J, et al. State generic substitution laws can lower drug outlays under Medicaid. Health Aff (Millwood). 2010;29(7):1383-1390.
23. Kanavos P, Costa-Font J, Seeley E. Competition in off-patent drug markets: issues, regulation and evidence. Econ Policy. 2008;23:500-544.
24. Food and Drug Administration (FDA). Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. Silver Spring, MD: FDA; 2015. http://www.accessdata.fda.gov/scripts/cder/ob/. Accessed September 27, 2015.
25. Laoutidis ZG, Kioulos KT. Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis. Pharmacopsychiatry. 2015;48 (6):187-199.
26. Green JB, Ross JS, Jackevicius CA, Shah ND, Krumholz HM. When choosing statin therapy: the case for generics. JAMA Intern Med. 2013;173(3): 229-232.
27. FDA warning letter: Bystolic (nebivolol) tablets. Silver Spring, MD: Food and Drug Administration; 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm054010.pdf. Accessed October 4, 2015.
28. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148 (1):16-29.
29. VA National Formulary. Washington, DC: Department of Veterans Affairs; 2015. http://www.pbm.va.gov/nationalformulary.asp. Accessed October 10, 2015.
30. WWAMI Rural Health Research Center. Rural-Urban Commuting Area (RUCA) Data, version 2.0. http://depts.washington.edu/uwruca/ruca-data.php. Accessed September 27, 2015.
31. American fact finder. Washington, DC: Census Bureau. http://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml. Accessed September 27, 2015.
32. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25) (suppl 2):S1-S45.
33. CMS releases prescriber-level Medicare data for first time. Baltimore, MD: Centers for Medicare & Medicaid Services; 2015. https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2015-Fact-sheets-items/2015-04-30.html. Accessed September 20, 2015.
34. Spingarn RW, Berlin JA, Strom BL. When pharmaceutical manufacturers' employees present grand rounds, what do residents remember? Acad Med. 1996;71(1):86-88.
35. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271(9):684-689.
36. Lublóy Á. Factors affecting the uptake of new medicines: a systematic literature review. BMC Health Serv Res. 2014;14:469.
37. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995;273(16):1296-1298.
38. Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med. 1996;5 (4):201-206.
39. Pharmaceutical Research and Manufacturers of America (PhRMA). Code on interactions with health care professionals. Washington, DC: PhRMA; 2008. http://www.phrma.org/principles-guidelines/code-on-interactions-with-health-care-professionals. Accessed December 15, 2015.
40. O'Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2007;CD000409(4): CD000409.
41. Burnand B. Independent drug bulletins to promote the prescription of appropriate drugs: a necessary but difficult task. Bull World Health Organ. 2013;91(6):391-391A.